Maintenance of Paternal Methylation and Repression of the Imprinted H19 Gene Requires MBD3

por Reese, Kimberly J, Lin, Shu, Verona, Raluca I, Schultz, Richard M, Bartolomei, Marisa S
Publicado 2007

Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer

por Martinez, Marina, Kim, Soyeon, St. Jean, Naomi, O’Brien, Shaun, Lian, Lurong, Sun, Jing, Verona, Raluca I., Moon, Edmund
Publicado 2021

TIM-3 Suppresses Anti-CD3/CD28-Induced TCR Activation and IL-2 Expression through the NFAT Signaling Pathway

por Tomkowicz, Brian, Walsh, Eileen, Cotty, Adam, Verona, Raluca, Sabins, Nina, Kaplan, Fred, Santulli-Marotto, Sandy, Chin, Chen-Ni, Mooney, Jill, Lingham, Russell B., Naso, Michael, McCabe, Timothy
Publicado 2015

Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti–programmed cell death protein-1 (PD-1) antibody, in human cancer models

por DeAngelis, Nikki, Ferrante, Catherine, Powers, Gordon, Sendecki, Jocelyn, Mattson, Bethany, Pizutti, Darlene, Packman, Kathryn, Wang, Weirong, Trouba, Kevin, Nanjunda, Rupesh, Wheeler, John, Brittingham, Ray, Wu, Sheng-Jiun, Luo, Jinquan, Lorenzi, Matthew V., Verona, Raluca I.
Publicado 2022

Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma

por Girgis, Suzette, Wang Lin, Shun Xin, Pillarisetti, Kodandaram, Verona, Raluca, Vieyra, Diego, Casneuf, Tineke, Fink, Damien, Miao, Xin, Chen, Yang, Stephenson, Tara, Banerjee, Arnob, Hilder, Brandi W., Russell, Jeffery, Infante, Jeffrey, Elsayed, Yusri, Smit, Jennifer, Goldberg, Jenna D.
Publicado 2022

P892: ANALYSIS OF INFECTIONS AND PARAMETERS OF HUMORAL IMMUNITY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH TALQUETAMAB (TAL) MONOTHERAPY IN MON...

por Rasche, Leo, Schinke, Carolina, Chari, Ajai, Lipe, Brea C., Lavi, Noa, Rodríguez-Otero, Paula, Vishwamitra, Deeksha, Skerget, Sheri, Verona, Raluca, MA, Xuewen, Khedkar, Sheetal, Hilder, Brandi, Masterson, Tara, Campagna, Michela, Renaud, Thomas, Tolbert, Jaszianne, Heuck, Christoph, Smit, Damiette, van de Donk, Niels W.C.J.
Publicado 2023

P1506: TECLISTAMAB REDUCES POLYCLONAL IMMUNOGLOBULIN LEVELS AND IMPAIRS VACCINATION RESPONSES IN HEAVILY PRETREATED MM PATIENTS

por Frerichs, Kristine, Verkleij, Christie, Mateos, Maria-Victoria, Zweegman, Sonja, Groen, Kaz, Kuipers, Ilse, Martin, Tom, Rodriguez, Cesar, Nooka, Ajay, Kruijswijk, Sandy, Skerget, Sheri, Doyle, Margaret, Banerjee, Arnob, Chastain, Katherine, Perales-Puchalt, Alfredo, Stephenson, Tara, Uhlar, Clarissa, Kobos, Rachel, Verona, Raluca, van de Donk, Niels W.C.J.
Publicado 2023

P879: LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

por Sidana, Surbhi, Moreau, Philippe, Garfall, Alfred, Bhutani, Manisha, Oriol, Albert, Nooka, Ajay, Martin, Tom, Rosiñol Dachs, Laura, Mateos, Maria-Victoria, Bahlis, Nizar J, Popat, Rakesh, Besemer, Britta, Martinez-Lopez, Joaquín, Krishnan, Amrita, Delforge, Michel, Trancucci, Danielle, Verona, Raluca, Stephenson, Tara, Chastain, Katherine, van de Donk, Niels W.C.J.
Publicado 2023

Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas

por Martens, Anne W.J., Rietveld, Joanne M., de Boer, Renate, Peters, Fleur S., Ngo, An, van Mil, Lotte W.H.G., de Heer, Koen, Spaargaren, Marcel, Verkleij, Christie P.M., van de Donk, Niels W.C.J., Adams, Homer C., Eldering, Eric, van Noesel, Carel J.M., Verona, Raluca, Kater, Arnon P.
Publicado 2022

Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1

por Miao, Xin, Wu, Liviawati S., Lin, Shun Xin Wang, Xu, Yan, Chen, Yang, Iwaki, Yuki, Kobos, Rachel, Stephenson, Tara, Kemmerer, Kristy, Uhlar, Clarissa M., Banerjee, Arnob, Goldberg, Jenna D., Trancucci, Danielle, Apte, Amit, Verona, Raluca, Pei, Lixia, Desai, Rachit, Hickey, Kathleen, Su, Yaming, Ouellet, Daniele, Samtani, Mahesh N., Guo, Yue, Garfall, Alfred L., Krishnan, Amrita, Usmani, Saad Z., Zhou, Honghui, Girgis, Suzette
Publicado 2023

Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes

por Bustoros, Mark, Anand, Shankara, Sklavenitis-Pistofidis, Romanos, Redd, Robert, Boyle, Eileen M., Zhitomirsky, Benny, Dunford, Andrew J., Tai, Yu-Tzu, Chavda, Selina J., Boehner, Cody, Neuse, Carl Jannes, Rahmat, Mahshid, Dutta, Ankit, Casneuf, Tineke, Verona, Raluca, Kastritis, Efstathis, Trippa, Lorenzo, Stewart, Chip, Walker, Brian A., Davies, Faith E., Dimopoulos, Meletios-Athanasios, Bergsagel, P. Leif, Yong, Kwee, Morgan, Gareth J., Aguet, François, Getz, Gad, Ghobrial, Irene M.
Publicado 2022

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma

por Verkleij, Christie P.M., Frerichs, Kristine A., Broekmans, Marloes E.C., Duetz, Carolien, O’Neill, Chloe A., Bruins, Wassilis S.C., Homan-Weert, Paola M., Minnema, Monique C., Levin, Mark-David, Broijl, Annemiek, Bos, Gerard M.J., Kersten, Marie José, Klein, Saskia K., Shikhagaie, Medya M., Casneuf, Tineke, Abraham, Yann, Smets, Tina, Vanhoof, Greet, Cortes-Selva, Diana, van Steenbergen, Laure, Ramos, Elena, Verona, Raluca I., Krevvata, Maria, Sonneveld, Pieter, Zweegman, Sonja, Mutis, Tuna, van de Donk, Niels W.C.J.
Publicado 2023